Literature DB >> 22311282

Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer.

Charles C Hsu1, Christopher L Wolfgang, Daniel A Laheru, Timothy M Pawlik, Michael J Swartz, Jordan M Winter, Raymond Robinson, Barish H Edil, Amol K Narang, Michael A Choti, Ralph H Hruban, John L Cameron, Richard D Schulick, Joseph M Herman.   

Abstract

BACKGROUND: Identifying pancreatic cancer patients at high risk of early mortality following pancreaticoduodenectomy (PD) is important for treatment decisions in a multidisciplinary setting. This study examines the preoperative predictors of early mortality following PD and combines these variables into an early mortality risk score (EMRS).
METHODS: Medical records of patients who underwent PD for pancreatic adenocarcinoma at the Johns Hopkins Hospital between 30 August 1993 and 28 February 2005 were reviewed. Cox proportional hazards analysis was performed to identify predictors of early mortality, defined as death at 9 and 12 months. EMRS was constructed from univariate associated risk factors (age >75 years, tumor size ≥ 3 cm, poor differentiation, co-morbid diseases) with each factor assigned 1 point (range of 0-4). EMRS was evaluated as an independent predictor of death at 9 and 12 months.
RESULTS: On univariate analysis, risk factors for death at 9 months included age ≥ 75 years (RR, 1.6; p = .009), comorbid disease (RR, 1.5; p = 0.020), tumor ≥ 3 cm (RR, 1.4; P = 0.050), and poor differentiation (RR, 2.1; P < 0.001). EMRS was associated with early mortality among those who did (p = 0.038) and did not receive adjuvant treatment (p < 0.001). A modified EMRS without tumor differentiation was also associated with early mortality (p < 0.001). Results persisted when reanalyzed using death at 12 months.
CONCLUSIONS: EMRS may identify patients at risk of early mortality following PD who may be candidates for alternatively sequenced treatment protocols. Prospective validation of this EMRS is needed.

Entities:  

Mesh:

Year:  2012        PMID: 22311282      PMCID: PMC3561732          DOI: 10.1007/s11605-011-1811-4

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  29 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

Authors:  Mark P Callery; Kenneth J Chang; Elliot K Fishman; Mark S Talamonti; L William Traverso; David C Linehan
Journal:  Ann Surg Oncol       Date:  2009-04-24       Impact factor: 5.344

3.  Resectable pancreatic cancer: who really benefits from resection?

Authors:  Giuliano Barugola; Stefano Partelli; Stefano Marcucci; Nora Sartori; Paola Capelli; Claudio Bassi; Paolo Pederzoli; Massimo Falconi
Journal:  Ann Surg Oncol       Date:  2009-12       Impact factor: 5.344

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer.

Authors:  Christopher H Crane; Gauri Varadhachary; Robert A Wolff; Peter W T Pisters; Douglas B Evans
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006-04       Impact factor: 3.043

6.  Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).

Authors:  Michele M Corsini; Robert C Miller; Michael G Haddock; John H Donohue; Michael B Farnell; David M Nagorney; Aminah Jatoi; Robert R McWilliams; George P Kim; Sumita Bhatia; Matthew J Iott; Leonard L Gunderson
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

7.  Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.

Authors:  Joseph M Herman; Michael J Swartz; Charles C Hsu; Jordan Winter; Timothy M Pawlik; Elizabeth Sugar; Ray Robinson; Daniel A Laheru; Elizabeth Jaffee; Ralph H Hruban; Kurtis A Campbell; Christopher L Wolfgang; Fariba Asrari; Ross Donehower; Manuel Hidalgo; Luis A Diaz; Charles Yeo; John L Cameron; Richard D Schulick; Ross Abrams
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

8.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.

Authors:  Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie Abdalla; Huamin Wang; Gregg A Staerkel; Jeffrey H Lee; William A Ross; Eric P Tamm; Priya R Bhosale; Sunil Krishnan; Prajnan Das; Linus Ho; Henry Xiong; James L Abbruzzese; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

9.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Authors:  Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

10.  Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.

Authors:  Matthew H G Katz; Huamin Wang; Jason B Fleming; Charlotte C Sun; Rosa F Hwang; Robert A Wolff; Gauri Varadhachary; James L Abbruzzese; Christopher H Crane; Sunil Krishnan; Jean-Nicolas Vauthey; Eddie K Abdalla; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2009-02-05       Impact factor: 5.344

View more
  24 in total

1.  External assessment of the Early Mortality Risk Score in patients with adenocarcinoma undergoing pancreaticoduodenectomy.

Authors:  Gaëtan-Romain Joliat; David Petermann; Nicolas Demartines; Markus Schäfer
Journal:  HPB (Oxford)       Date:  2015-04-23       Impact factor: 3.647

2.  Implementation and Evaluation of a Clinical Pathway for Pancreaticoduodenectomy Procedures: a Prospective Cohort Study.

Authors:  Marion van der Kolk; Mark van den Boogaard; Femke Becking-Verhaar; Hettie Custers; Hans van der Hoeven; Peter Pickkers; Kees van Laarhoven
Journal:  J Gastrointest Surg       Date:  2017-06-06       Impact factor: 3.452

3.  Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.

Authors:  Sadaki Asari; Ippei Matsumoto; Hirochika Toyama; Makoto Shinzeki; Tadahiro Goto; Jun Ishida; Tetsuo Ajiki; Takumi Fukumoto; Yonson Ku
Journal:  Surg Today       Date:  2015-06-25       Impact factor: 2.549

Review 4.  Recent progress in pancreatic cancer.

Authors:  Christopher L Wolfgang; Joseph M Herman; Daniel A Laheru; Alison P Klein; Michael A Erdek; Elliot K Fishman; Ralph H Hruban
Journal:  CA Cancer J Clin       Date:  2013-07-15       Impact factor: 508.702

5.  Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.

Authors:  Maria Celeste Palmarocchi; Ruben Carlo Balzarotti Canger; Piercarlo Saletti
Journal:  Oncol Lett       Date:  2017-04-11       Impact factor: 2.967

6.  Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality.

Authors:  Yoshihiro Mise; Jean-Nicolas Vauthey; Giuseppe Zimmitti; Nathan H Parker; Claudius Conrad; Thomas A Aloia; Jeffrey E Lee; Jason B Fleming; Matthew Harold G Katz
Journal:  Ann Surg       Date:  2015-12       Impact factor: 12.969

Review 7.  Early Detection of Pancreatic Cancer: Opportunities and Challenges.

Authors:  Aatur D Singhi; Eugene J Koay; Suresh T Chari; Anirban Maitra
Journal:  Gastroenterology       Date:  2019-02-02       Impact factor: 22.682

8.  The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma.

Authors:  Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss
Journal:  Ann Surg Oncol       Date:  2014-04-26       Impact factor: 5.344

9.  Opportunities of improvement in the management of pancreatic and periampullary tumors.

Authors:  Tom Nordby; Tone Ikdahl; Inger Marie Bowitz Lothe; Kim Ånonsen; Truls Hauge; Bjørn Edwin; Pål-Dag Line; Knut Jørgen Labori; Trond Buanes
Journal:  Scand J Gastroenterol       Date:  2013-05       Impact factor: 2.423

10.  Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN.

Authors:  Ying Liu; Sukhwinder Kaur; Ying Huang; Johannes F Fahrmann; Jo Ann Rinaudo; Samir M Hanash; Surinder K Batra; Aatur D Singhi; Randall E Brand; Anirban Maitra; Brian B Haab
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-06-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.